---
title: "《盈警》北森控股虧損大減  上半年最多蝕 2,380 萬人民幣"
description: "北森控股發盈警，預計 6 月止六個月虧損介乎 1,460 萬至 2,380 萬人民幣，相較上年同期虧損 9,900 萬人民幣，降幅介乎 76%-85%。主要由於以股份為基礎付款減少；及收入預計增加 15.2%-20.5%，至 5.03 億至 5.26 億人民幣。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262266122.md"
published_at: "2025-10-22T14:00:12.000Z"
---

# 《盈警》北森控股虧損大減  上半年最多蝕 2,380 萬人民幣

> 北森控股發盈警，預計 6 月止六個月虧損介乎 1,460 萬至 2,380 萬人民幣，相較上年同期虧損 9,900 萬人民幣，降幅介乎 76%-85%。主要由於以股份為基礎付款減少；及收入預計增加 15.2%-20.5%，至 5.03 億至 5.26 億人民幣。

北森控股 (09669.HK) 發盈警，預計 6 月止六個月虧損介乎 1,460 萬至 2,380 萬人民幣，相較上年同期虧損 9,900 萬人民幣，降幅介乎 76%-85%。主要由於以股份為基礎付款減少；及收入預計增加 15.2%-20.5%，至 5.03 億至 5.26 億人民幣。

### Related Stocks

- [09669.HK - 北森控股](https://longbridge.com/zh-HK/quote/09669.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy | Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY | [Link](https://longbridge.com/zh-HK/news/276401882.md) |
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/zh-HK/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-HK/news/276393466.md) |
| Berkshire Hathaway discloses investment in New York Times | Berkshire Hathaway has disclosed a new investment in the New York Times, reentering a sector it left in 2020. The compan | [Link](https://longbridge.com/zh-HK/news/276173033.md) |
| 04:38 ETAcceleronix e IDEMIA Secure Transactions lanzan el programa de acceso anticipado IFPP | Acceleronix and IDEMIA Secure Transactions have launched the IFPP Early Access Program at MWC26 Barcelona, in collaborat | [Link](https://longbridge.com/zh-HK/news/276429430.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。